Anlotinib as a molecular targeted therapy for tumors
Y Gao, P Liu, R Shi - Oncology Letters, 2020 - spandidos-publications.com
Angiogenesis has an essential role in tumor growth and metastasis, and blocking this
pathway has been a successfully utilized strategy in the clinical treatment of cancer …
pathway has been a successfully utilized strategy in the clinical treatment of cancer …
Role of indole scaffolds as pharmacophores in the development of anti-lung cancer agents
Lung cancer is the leading cause of death in men and women worldwide, affecting millions
of people. Between the two types of lung cancers, non-small cell lung cancer (NSCLC) is …
of people. Between the two types of lung cancers, non-small cell lung cancer (NSCLC) is …
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
X Zhang, L Zeng, Y Li, Q Xu, H Yang, A Lizaso… - Cancer Immunology …, 2021 - Springer
Background This study evaluated the efficacy and safety of anlotinib combined with
programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer …
programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer …
Therapeutic potential of indole alkaloids in respiratory diseases: A comprehensive review
Background Indole alkaloids are very promising for potential therapeutic purposes and
appear to be particularly effective against respiratory diseases. Several experimental studies …
appear to be particularly effective against respiratory diseases. Several experimental studies …
Synthesis of novel indole-isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines
Background Liver cancer is predicted to be the sixth most diagnosed cancer globally and
fourth leading cause of cancer deaths. In this study, a series of indole-3-isoxazole-5 …
fourth leading cause of cancer deaths. In this study, a series of indole-3-isoxazole-5 …
Real-world efficacy and safety of anlotinib with and without immunotherapy in advanced non-small cell lung cancer
Q Xiong, B Qin, L Xin, B Yang, Q Song, Y Wang… - Frontiers in …, 2021 - frontiersin.org
Aims Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic
effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to …
effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to …
Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma
W Zhou, Y Gao, Y Tong, Q Wu, Y Zhou, Y Li - Pharmacological Research, 2021 - Elsevier
Anlotinib is a novel molecular targeted drug that has been approved for the treatment of lung
adenocarcinoma. Currently these agents are rarely used in the treatment of lung squamous …
adenocarcinoma. Currently these agents are rarely used in the treatment of lung squamous …
Efficacy and safety of anlotinib in advanced non-small cell lung cancer: a real-world study
K Zhang, X Ma, H Gao, H Wang, H Qin… - Cancer management …, 2020 - Taylor & Francis
Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …
inhibitor, administered as third-line or further treatment prolonged progression-free survival …
Efficacy and safety of anlotinib for patients with advanced NSCLC who progressed after standard regimens and the preliminary analysis of an efficacy predictor
JD Cheng, LX Chai, ZP Zhao, YY Hao… - Cancer management and …, 2020 - Taylor & Francis
Background The aim of this study was to investigate the efficacy and safety of anlotinib for
patients with advanced non-small cell lung cancer (NSCLC) who progressed after standard …
patients with advanced non-small cell lung cancer (NSCLC) who progressed after standard …
Anlotinib for patients with small cell lung cancer and baseline liver metastases: a post hoc analysis of the ALTER 1202 trial
Y Cheng, Q Wang, K Li, J Shi, L Wu, B Han… - Cancer …, 2022 - Wiley Online Library
Liver metastasis is common in advanced small cell lung cancer (SCLC). There is no
evidence‐proven treatment beyond the second line in patients with SCLC and liver …
evidence‐proven treatment beyond the second line in patients with SCLC and liver …